Neo-Imuntech, first administration of NT-I7 and Kitruda combined solid cancer treatment for patients in phase 2 clinical trials
Neo-Imuntech public offering price of 7500 won confirmed… Institutional Investor Demand Forecast Competition 1374 to 1